Compare DexCom, Inc. (DXCM) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

LBTYK trades at $10.49, up 1.16% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported a significant net loss of -$7.14B in 2025 despite $4.88B revenue, though Q1 2026 showed improvement with a positive EPS beat. Analyst sentiment remains strongly bullish with 69% buy ratings, driven by the planned 2027 Ziggo Group spin-off as a key catalyst.

The stock presents a high-risk opportunity with potential upside from sum-of-the-parts valuation and spin-off catalysts, but faces substantial execution risks given persistent losses and competitive telecom pressures. Current valuation metrics (P/S 0.72, P/B 0.37) suggest deep discount to intrinsic value if restructuring succeeds.